[
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this blog"
  },
  {
    "objectID": "posts/trialMM/index.html",
    "href": "posts/trialMM/index.html",
    "title": "Myeloma Multiple trials",
    "section": "",
    "text": "This are the requested trials to Vivli.\n\nTOURMALINE-MM1: Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.https://doi.org/10.1200/JCO.21.009. ClinicalTrials.gov ID, NCT01564537. Other Study ID Numbers: C16010\nTOURMALINE-MM2: Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.https://doi.org/10.1182/blood.2020008787. ClinicalTrials.gov ID, NCT01850524. Other Study ID Numbers: C16014"
  },
  {
    "objectID": "posts/studies-for-simulation/index.html",
    "href": "posts/studies-for-simulation/index.html",
    "title": "Studies for data simulation",
    "section": "",
    "text": "Those are the potential data sources.\n\nStudies of comparartive effectiveness:\n\n\nJoseph et al. (2020)\nDuarte et al. (2021)\nDavies et al. (2021)\nMinarik et al. (2021)\nTouzeau et al. (2021)\nSokol et al. (2022)\nMinarik et al. (2022)\nLoponen et al. (2023)\nLudwig et al. (2024)\nFric et al. (2024)\n\n\nStudies MM characteristics:\n\n\nChari et al. (2020)\nMunshi et al. (2020)\nMian et al. (2023)\nTerebelo et al. (2024)\n\n\nOn diagnosis, management, and treatment:\n\n\nChng et al. (2024)\nRajkumar (2024)\nAbduh (2024)\nRafae, Rhee, and Al Hadidi (2024)\n\n\n\nFacts\nIn the USA. Cancer gov\nMore stats: SEER\n\nRate of New Cases and Deaths per 100,000: The rate of new cases of myeloma was 7.2 per 100,000 men and women per year. The death rate was 3.0 per 100,000 men and women per year. These rates are age-adjusted and based on 2017–2021 cases and 2018–2022 deaths.\nLifetime Risk of Developing Cancer: Approximately 0.8 percent of men and women will be diagnosed with myeloma at some point during their lifetime, based on 2018–2021 data, excluding 2020 due to COVID.\nPrevalence of This Cancer: In 2021, there were an estimated 179,063 people living with myeloma in the United States.\n\n\n\n\n\n\nReferences\n\nAbduh, Maisa Siddiq. 2024. “An Overview of Multiple Myeloma: A Monoclonal Plasma Cell Malignancy’s Diagnosis, Management, and Treatment Modalities.” Saudi Journal of Biological Sciences 31 (2): 103920. https://www.sciencedirect.com/science/article/pii/S1319562X23003650?via%3Dihub.\n\n\nChari, Ajai, Dorothy Romanus, Antonio Palumbo, Marlo Blazer, Eileen Farrelly, Aditya Raju, Hui Huang, and Paul Richardson. 2020. “Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia 20 (1): 8–17. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)32012-9/fulltext.\n\n\nChng, Wee-Joo, Chandramouli Nagarajan, Shang-Yi Huang, Pankaj Malhotra, Yu-Yan Hwang, Vivian Blunk, Manmohan Singh, and Lin Wang. 2024. “A Systematic Review on the Epidemiology and Treatment Options of Multiple Myeloma in Asia.” Heliyon. https://www.sciencedirect.com/science/article/pii/S2405844024157295.\n\n\nDavies, Faith, Robert Rifkin, Caitlin Costello, Gareth Morgan, Saad Usmani, Rafat Abonour, Antonio Palumbo, et al. 2021. “Real-World Comparative Effectiveness of Triplets Containing Bortezomib (b), Carfilzomib (c), Daratumumab (d), or Ixazomib (i) in Relapsed/Refractory Multiple Myeloma (RRMM) in the US.” Annals of Hematology 100 (9): 2325–37.\n\n\nDuarte, Patricio Jose, Natalia Paola Schutz, Paola Ochoa, Sebastian Yantorno, Sergio Orlando, Sergio Lopresti, Soledad Zabaljauregui, et al. 2021. “Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma Patients with Lenalidomide-Dexamethasone Combinations in a Latin American Country. A Retrospective Cohort Study from Grupo Argentino de Mieloma múltiple.” Expert Review of Hematology 14 (3): 315–22.\n\n\nFric, Dominik, Martin Stork, Ivanna Boichuk, Viera Sandecka, Zdenek Adam, Marta Krejci, Eva Ondrouskova, et al. 2024. “Efficacy of Ixazomib, Lenalidomide, Dexamethasone Regimen in Daratumumab-Exposed Relapsed/Refractory Multiple Myeloma Patients: A Retrospective Analysis.” European Journal of Haematology 113 (6): 810–16. https://doi.org/https://doi.org/10.1111/ejh.14292.\n\n\nJoseph, Nisha S, Jonathan L Kaufman, Madhav V Dhodapkar, Craig C Hofmeister, Dhwani K Almaula, Leonard T Heffner, Vikas A Gupta, Lawrence H Boise, Sagar Lonial, and Ajay K Nooka. 2020. “Long-Term Follow-up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.” Journal of Clinical Oncology 38 (17): 1928–37.\n\n\nLoponen, Heidi, Juha Mehtälä, Tero Ylisaukko-oja, Oscar Brück, Kimmo Porkka, Perttu Koskenvesa, Kirsi Saukkonen, and Juha Lievonen. 2023. “Real-World Experience of Novel Multiple Myeloma Treatments in a Large, Single-Center Cohort in Finland.” EJHaem 4 (4): 1019–29.\n\n\nLudwig, Heinz, Karthik Ramasamy, Marı́a-Victoria Mateos, Bhuvan Kishore, Varga Gergely, Miriam Ladicka, Alessandra Ori, et al. 2024. “Use via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.” Doi: 10.1016/j.clml.2023.10.003. Clinical Lymphoma, Myeloma and Leukemia 24 (2): e40–e49.e3. https://doi.org/10.1016/j.clml.2023.10.003.\n\n\nMian, Hira, Arleigh McCurdy, Smith Giri, Shakira Grant, Bram Rochwerg, Erica Winks, Ashley E Rosko, et al. 2023. “The Prevalence and Outcomes of Frail Older Adults in Clinical Trials in Multiple Myeloma: A Systematic Review.” Blood Cancer Journal 13 (1): 6. https://www.nature.com/articles/s41408-022-00779-2.\n\n\nMinarik, Jiri, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, et al. 2021. “Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice.” BMC Cancer 21: 1–13.\n\n\nMinarik, Jiri, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, et al. 2022. “Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-up Analysis and the Results of Subsequent Therapy.” Cancers 14 (20): 5165.\n\n\nMunshi, Nikhil C, Herve Avet-Loiseau, Kenneth C Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios Dimopoulos, et al. 2020. “A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma.” Blood Advances 4 (23): 5988–99. https://ashpublications.org/bloodadvances/article/4/23/5988/474415/A-large-meta-analysis-establishes-the-role-of-MRD.\n\n\nRafae, Abdul, Frits van Rhee, and Samer Al Hadidi. 2024. “Perspectives on the Treatment of Multiple Myeloma.” The Oncologist 29 (3): 200–212. https://academic.oup.com/oncolo/article/29/3/200/7444336?login=false.\n\n\nRajkumar, S Vincent. 2024. “Multiple Myeloma: 2024 Update on Diagnosis, Risk-Stratification, and Management.” American Journal of Hematology 99 (9): 1802–24. https://onlinelibrary.wiley.com/doi/10.1002/ajh.27422.\n\n\nSokol, Juraj, Tomas Guman, Juraj Chudej, Monika Hlebaskova, Natalia Stecova, Lubica Valekova, Monika Kucerikova, and Jan Stasko. 2022. “Ixazomib, Lenalidomide, and Dexamethasone Combination in ‘Real-World’ Clinical Practice in Patients with Relapsed/Refractory Multiple Myeloma.” Annals of Hematology, 1–9.\n\n\nTerebelo, Howard R, James Omel, Lynne I Wagner, James W Hardin, Robert M Rifkin, Sikander Ailawadhi, Brian GM Durie, et al. 2024. “Characteristics and Treatment Patterns of Long-Surviving Patients with Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry.” Clinical Lymphoma Myeloma and Leukemia. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(24)02401-7/fulltext.\n\n\nTouzeau, Cyrille, Nadia Quignot, Jie Meng, Heng Jiang, Artak Khachatryan, Moushmi Singh, Vanessa Taieb, Jean-Vannak Chauny, and Gaëlle Désaméricq. 2021. “Survival and Treatment Patterns of Patients with Relapsed or Refractory Multiple Myeloma in France —a Cohort Study Using the French National Healthcare Database (SNDS).” Annals of Hematology 100 (7): 1825–36. https://doi.org/10.1007/s00277-021-04522-y."
  },
  {
    "objectID": "posts/synthea-module/index.html",
    "href": "posts/synthea-module/index.html",
    "title": "Synthea Module",
    "section": "",
    "text": "Acute Mieloma Leukemia \nThis is the final report from the Health for the Office of the National Coordinator for Health Information Technology. They also prepared the module Companion Guide for AML.\nThe McCormick’s paper"
  },
  {
    "objectID": "posts/synthea-module/index.html#the-visio-diagram",
    "href": "posts/synthea-module/index.html#the-visio-diagram",
    "title": "Synthea Module",
    "section": "The Visio Diagram",
    "text": "The Visio Diagram"
  },
  {
    "objectID": "posts/synthea-module/index.html#define-the-modules-states",
    "href": "posts/synthea-module/index.html#define-the-modules-states",
    "title": "Synthea Module",
    "section": "Define the modules states",
    "text": "Define the modules states\nMyeloma Multple States need to provide details about each clinical state modeled. Table provided information on that.\n\n\n\n\n\n\n\n\n\nState Name\nType\nState Details\nCodification\n\n\n\n\nInitial\nInitial\nInitial module required by Synthea\nn/a\n\n\n\nDelay\nDelay in years for a percentage of the individuas after birth before progressing to blank state\nn/a"
  },
  {
    "objectID": "posts/synthea-module/index.html#modules-parameters",
    "href": "posts/synthea-module/index.html#modules-parameters",
    "title": "Synthea Module",
    "section": "Modules parameters",
    "text": "Modules parameters\nModule Parameters summarizes the probabilities used to construct the module. A state moves to another considering each branch, the values that each branch takes can range from 0-1, and multiples branch are present, their sum should be 1. This are probabilities.\n\n\n\nParameter\nValue\nComments/ref\n\n\n\n\nProbability of age at time of MM diagnosis\n1\nn/a"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Trend-Revival",
    "section": "",
    "text": "Studies for data simulation\n\n\n\n\n\n\nstudies\n\n\nRWD\n\n\nanalysis\n\n\n\n\n\n\n\n\n\nJan 3, 2025\n\n\nIgnacio Leiva\n\n\n\n\n\n\n\n\n\n\n\n\nSynthea Module\n\n\n\n\n\n\nnews\n\n\nRWD\n\n\n\n\n\n\n\n\n\nJan 3, 2025\n\n\nIgnacio Leiva\n\n\n\n\n\n\n\n\n\n\n\n\nMyeloma Multiple trials\n\n\n\n\n\n\ntrial\n\n\nRCT\n\n\n\n\n\n\n\n\n\nJan 3, 2025\n\n\nIgnacio Leiva\n\n\n\n\n\n\nNo matching items"
  }
]